IVOIGERCC
- Conditions
- nresectable or metastatic renal cell carcinoma
- Registration Number
- JPRN-jRCTs031180024
- Lead Sponsor
- Onishi Hiroshi
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Primary registration
1)Cytologically or histologically confirmed renal cell carcinoma.or clinically judged as renal cell carcinoma. 2)At least two measurable lesions excluding only lung lesions. 3)Radical operation not applicable 4)Favorable risk: Treatment is either cancelled or complete after the initial treatment; no other prioritized chemotherapy can be applied; any applicable chemotherapy is rejected. Intermediate/poor risk: No other prioritized chemotherapy can be applied after the initial treatment; suitable chemotherapy is not applicable for some reason; suitable chemotherapy is rejected by the patient. 5)Immediate Radiotherapy not applicable 6)Men and women aged 20 or more 7)ECOG Performance status of 0-2 8)Judgement by Radiation-oncologist for indication and safely of irradiation 9)Satisfication of the following criteria in the latest labo data within 7 days of the registration:1.WBC=2000 per uL or more,2.Hb=9.0g per dL or more, 3.PLT=50000 per uL or more, 4.Serum Creatinine=3.0mg per dL or less and eGFR 30mL/min or more 5.Total bililubine=1.5mg per dL or less, 6.GOT(AST)=100IU per L or less, 7.GPT(ALT)=100IU per L or less, 8.SpO2=93% or more(room air) 10)Written informed consent after enough explanation
Secondary registration
Among the primary registered patients with completion of initial treatment protocol, at the evaluation just before the second registration after the first cycle, no observation of interstitial pneumonitis (Grade 2 or more), acute kidney injury (Grade 4 or more), or other fatal toxicities (Grade 3 or more) , according to the NCI-CTCAE v4.0.
Primary regisration
1)Active double cancer(except for some early or cured cancer as followe:carcinoma in situ, mucosal cancer, stage I prostate, breast, or laryngeal cancer) 2)Serious heart disease,uncontrolled diabetes mellitus despite continuing treatment of insulin,cardiac infarction within 6 months before enrollment,uncontrolled hypertension,history of severe infections,watery diarrhea,paresis of intestine,ileus,autoimmune disease,other severe complications 3)Radiographically (chest X-P or CT image) confirmed interstitial pneumonitis or pulmonary fibrosis 4)Severe emphysema, chronic bronchitis, asthma 5)Continuous systemic administration of steroid 6)Severe mental illness 7)women who are or may be pregnant or in lactatoin 8)Unsuitable patients judged by the attending physician or radiation-oncologist(previous irradiation is ignored) 9)A history of pretreatment within 7 days before the start of first Nivolumab
Secondary registration
1) Tumor progression, or decreasing of the ECOG performance status less than 3
2) Principal Investigator will end the protocol, when tumor progression, or significant fatal or life-threatening toxicities were observed.
3) Disappearance of the irradiation site.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method